Table 1.
Recipient and Donor Characteristics in the Development and Validation Cohorts
| Characteristic | Development | Validation | |
|---|---|---|---|
|
| |||
| n=18,099 | n=14,538 | n=7,502 | |
|
| |||
|
Recipient
| |||
| Age at LT* [mean (SD)] | 52 (8) | 52 (8) | 55 (6) |
| Male (%) | 75 | 75 | 76 |
| Race* (%) | |||
| Caucasian | 74 | 74 | 70* |
| African American (AA) | 9 | 9 | 12 |
| Other | 18 | 18 | 18 |
| HCC* (%) | 28 | 29 | 37* |
| Life support at LT* (%) | 3 | 3 | 4 |
| Diabetes* (%) | 18 | 18 | 21 |
| Lab MELD at LT* [median (IQR)] | 17 (12–23) | 17 (12–23) | 18 (12–26) |
| Serum creatinine at LT* [median (IQR)] | 1.0 (0.8–1.4) | 1.0 (0.8–1.3) | 1.0 (0.8–1.5) |
| Albumin at LT* [mean (SD)] | 2.8 (0.7) | 2.8 (0.7) | 3.0 (0.7) |
|
| |||
|
Donor
| |||
| Age at donation* [mean (SD)] | 40 (17) | 40 (17) | 41 (15) |
| Male* (%) | 62 | 62 | 60 |
| Race* (%) | |||
| Caucasian | 71 | 72 | 66 |
| African American (AA) | 13 | 13 | 18 |
| Other | 15 | 15 | 16 |
| Cause of death* (%) | |||
| Anoxia | 12 | 12 | 24 |
| Stroke | 43 | 43 | 40 |
| Trauma | 42 | 42 | 34 |
| Other | 3 | 3 | 3 |
| Anti-CMV positive (%) | 65 | 65 | 65 |
| Anti-HCV positive* (%) | 5 | 5 | 7 |
| Anti-HBc positive* (%) | 6 | 6 | 7 |
| DCD* (%) | 3 | 3 | 6 |
| Antihypertensives within 24 hrs pre-cross clamp* (%) | 18 | 18 | 23 |
| History cigarette smoking, @ >20 pack-yrs* (%) | 37 | 38 | 28 |
| Diabetes* (%) | 7 | 8 | 11 |
| History of hypertension* (%) | 28 | 29 | 35 |
| History of cancer (%) | 3 | 3 | 3 |
| Synthetic antidiuretic hormone* (%) | 31 | 31 | 16 |
| Cardiac arrest post brain death* (%) | 4 | 4 | 7 |
| Share allocation* (%) | |||
| Local | 75 | 74 | 77 |
| Regional | 19 | 20 | 19 |
| National | 6 | 6 | 4 |
| Donor (D) : Recipient (R) race combination* (%) | |||
| D non-AA : R non-AA | 80 | 80 | 73 |
| D AA : R AA | 2 | 2 | 3 |
| D AA : R non-AA | 12 | 12 | 15 |
| D non-AA : R AA | 7 | 7 | 9 |
| Cold ischemic time, hours* [mean (SD)] | 7.6 (2.8) | 7.6 (2.8) | 6.6 (2.5) |
| Height, cm* [mean (SD)] | 172 (11) | 172 (10) | 172 (10) |
| AST* [median (IQR)] | 44 (27–77) | 44 (27–77) | 45 (27–84) |
Recipient and donor characteristics in development cohort (without (n=18,099) and with (n=14,538) complete data on characteristics included in the final adjusted model) and validation cohort (n=7,502).
*
p<0.05 when testing for differences between demographic characteristic of development and validation cohorts.